0001104659-24-030157.txt : 20240301
0001104659-24-030157.hdr.sgml : 20240301
20240301204559
ACCESSION NUMBER: 0001104659-24-030157
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240301
DATE AS OF CHANGE: 20240301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Waddill William D.
CENTRAL INDEX KEY: 0001553338
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37852
FILM NUMBER: 24712594
MAIL ADDRESS:
STREET 1: C/O CALITHERA BIOSCIENCES
STREET 2: 343 OYSTER POINT BLVD, SUITE 200
CITY: SO. SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Protagonist Therapeutics, Inc
CENTRAL INDEX KEY: 0001377121
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 980505495
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560-1160
BUSINESS PHONE: (510) 474-0170
MAIL ADDRESS:
STREET 1: 7707 GATEWAY BLVD., SUITE 140
CITY: NEWARK
STATE: CA
ZIP: 94560-1160
FORMER COMPANY:
FORMER CONFORMED NAME: Protagonist Therapeutics Inc
DATE OF NAME CHANGE: 20130605
FORMER COMPANY:
FORMER CONFORMED NAME: Protagonist Inc
DATE OF NAME CHANGE: 20061002
4
1
tm247765-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-03-01
0
0001377121
Protagonist Therapeutics, Inc
PTGX
0001553338
Waddill William D.
C/O PROTAGONIST THERAPEUTICS, INC.
7707 GATEWAY BLVD., SUITE 140
NEWARK
CA
94560-1160
1
0
0
0
1
Common Stock
2024-03-01
4
M
0
12975
6.09
A
24975
D
Common Stock
2024-03-01
4
S
0
12975
31.34
D
12000
D
Stock Option (right to buy)
6.09
2024-03-01
4
M
0
12975
0.00
D
2026-07-16
Common Stock
12975
0
D
Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $30.46 to $31.99. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
These stock options are fully vested.
/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill
2024-03-01